Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

Cited by (727)

Items 101–200 of 727

1. Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
   Lee, Meng, Saver, Jeffrey L., Liao, Hung-Wei, Lin, Chun-Hsien, Ovbiagele, Bruce · 2017 · Stroke
2. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.
   S. Shadid, M. Jensen · 2003 · Diabetes Care
3. Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver disease
   Nicole J Barshop, Claude B. Sirlin, Jeffrey B. Schwimmer, Joel E. Lavine · 2008 · Alimentary Pharmacology & Therapeutics
4. Role of Lipotoxicity in Endothelial Dysfunction
   Jeong‐a Kim, Monica Montagnani, Sruti Chandrasekran, Michael J. Quon · 2012 · Heart Failure Clinics
5. Effects of Pioglitazone Versus Glipizide on Body Fat Distribution, Body Water Content, and Hemodynamics in Type 2 Diabetes
   Ananda Basu, Michael D. Jensen, Frances McCann, Debabrata Mukhopadhyay, Michael J. Joyner, Robert A. Rizza · 2006 · Diabetes Care
6. Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
   M. Bajaj, Swangjit Suraamornkul, Lou Jean Hardies, Leonard C. Glass, Nicolas Musi, Ralph Anthony DeFronzo · 2007 · Diabetologia
7. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone
   Ohki, Takamasa, Isogawa, Akihiro, Iwamoto, Masahiko, Ohsugi, Mitsuru, Yoshida, Haruhiko, Toda, Nobuo, Tagawa, Kazumi, Omata, Masao, Koike, Kazuhiko · 2012 · The Scientific World Journal
8. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
   Chiara Saponaro, Melania Gaggini, Amalia Gastaldelli · 2015 · Current Diabetes Reports
9. Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients
   Yoshinori Miyazaki, Helen He, Lawrence J. Mandarino, Ralph Anthony DeFronzo · 2003 · Diabetes
10. Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial
    Dorte Glintborg, Marianne Andersen, Claus Hagen, Lene Heickendorff, Anne Pernille Hermann · 2008 · The Journal of Clinical Endocrinology & Metabolism
11. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
    Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L.J. Visseren, Jan Westerink · 2017 · Cardiovascular Diabetology
12. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
    Matthias Herz, Don Johns, Jesús Reviriego, Loren David Grossman, Chantal Godin, Santiago Durán, Federico Gustavo Hawkins, Heather Anne Lochnan, F. Escobar‐Jiménez, Philip A Hardin et al. · 2003 · Clinical Therapeutics
13. Abdominal Obesity and Cardiovascular Disease: Is Inflammation the Missing Link?
    Jean‐Pierre Després · 2012 · Canadian Journal of Cardiology
14. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.
    Boden, Guenther, Homko, Carol, Mozzoli, Maria, Showe, Louise C., Nichols, Calen, Cheung, Peter · 2005 · Diabetes
15. Phytol/Phytanic Acid and Insulin Resistance: Potential Role of Phytanic Acid Proven by Docking Simulation and Modulation of Biochemical Alterations
    Mohamed Mohey Elmazar, Hanan Salah El-Abhar, Mona F. Schaalan, Nahla A. Farag · 2013 · PLoS ONE
16. In Vivo Actions of Peroxisome Proliferator–Activated Receptors
    Roy Eldor, Ralph A. DeFronzo, Muhammad A Abdul‐Ghani · 2013 · Diabetes Care
17. Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice
    Kana Araki, Takayuki Masaki, Isao Katsuragi, Katsuhiro Tanaka, Tetsuya Kakuma, Hironobu Yoshimatsu · 2006 · Hypertension
18. Pediatric Nonalcoholic Fatty Liver Disease in 2009
    Anna Alisi, Melania Manco, Andrea Vania, Valério Nobili · 2009 · The Journal of Pediatrics
19. Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions
    Nicholas P. Hays, Pietro Renato Galassetti, Robert H. Coker · 2008 · Pharmacology & Therapeutics
20. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113).
    K. Indulekha, R. Anjana, J. Surendar, V. Mohan · 2011 · Clinical Biochemistry
21. Caloric restriction, body fat and ageing in experimental models
    Das, M., Gabriely, I., Barzilai, N. · 2004 · Obesity Reviews
22. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor γ action on adipose tissue metabolism.
    Laplante, Mathieu, Festuccia, William T., Soucy, Geneviève, Gélinas, Yves, Lalonde, Josée, Berger, Joel P., Deshaies, Yves · 2006 · Diabetes
23. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects
    Ann Hammarstedt, Victoria Rotter Sopasakis, Silvia Gogg, Per‐Anders Jansson, Ulf Smith · 2004 · Diabetologia
24. Dyslipidemia in type 2 diabetes
    Ronald M. Krauss, Patty W. Siri · 2004 · Medical Clinics of North America
25. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression.
    N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. Elbein, P. Kern · 2006 · American Journal of Physiology. Endocrinology and Metabolism
26. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones
    Clifford J. Bailey · 2005 · Diabetes Obesity and Metabolism
27. Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk
    Birgit Gustafson, Ulf Smith · 2015 · Atherosclerosis
28. Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review
    Lluís Campins, M. Valero Camps, Ariadna Riera, Eulogio Pleguezuelos, Juan Carlos Yébenes, Mateu Serra‐Prat · 2016 · Pharmacology
29. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions
    Tiziana Caputo, Federica Gilardi, Béatrice Desvergne · 2017 · FEBS Letters
30. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Rafeeq Ali, Kenneth J. Cusi · 2009 · Annals of Medicine
31. Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity
    Kemp, David E., Ismail-Beigi, Faramarz, Ganocy, Stephen J., Conroy, Carla, Gao, Keming, Obral, Sarah, Fein, Elizabeth, Findling, Robert L., Calabrese, Joseph R. · 2012 · Journal of Affective Disorders
32. Prevention of Diabetes With Pioglitazone in ACT NOW
    DeFronzo, Ralph A., Tripathy, Devjit, Schwenke, Dawn C., Banerji, MaryAnn, Bray, George A., Buchanan, Thomas A., Clement, Stephen C., Gastaldelli, Amalia, Henry, Robert R., Kitabchi, Abbas E. et al. · 2013 · Diabetes
33. RETRACTED: Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation
    Massimo Collino, Manuela Aragno, Sara Castiglia, Gianluca Miglio, Chiara Elena Tomasinelli, Giuseppe Boccuzzi, Christoph Thiemermann, Roberto Fantozzi · 2010 · British Journal of Pharmacology · Retracted
34. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome
    Michio Shimabukuro, Hideaki Tanaka, Takeshi Shimabukuro · 2007 · Journal of Hypertension
35. A Licorice Ethanolic Extract with Peroxisome Proliferator-Activated Receptor-γ Ligand-Binding Activity Affects Diabetes in KK-Ay Mice, Abdominal Obesity in Diet-Induced Obese C57BL Mice and Hypertension in Spontaneously Hypertensive Rats
    Tatsumasa Mae, Mikio Kitahara, Tozo Nishiyama, Misuzu Tsukagawa, Eisaku Konishi, Hideyuki Kishida, Minpei Kuroda, Yoshihiro Mimaki, Yutaka Sashida, Kazuma Takahashi et al. · 2003 · Journal of Nutrition
36. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Harold Edward Bays, Lawrence Blonde, Robert S. Rosenson · 2006 · Expert Review of Cardiovascular Therapy
37. Clinical interest of PPARs ligands
    Bruno L Vergès · 2004 · Diabetes & Metabolism
38. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
    Diani, A. R., Sawada, Geri, Wyse, Beatrice, Murray, F. T., Khan, Mehmood · 2004 · American Journal of Physiology-Endocrinology and Metabolism
39. PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
    Gastaldelli, Amalia, Sabatini, Silvia, Carli, Fabrizia, Gaggini, Melania, Bril, Fernando, Belfort‐DeAguiar, Renata, Positano, Vincenzo, Barb, Diana, Kadiyala, Sushma, Harrison, Stephen et al. · 2021 · Liver International
40. PPARγand Its Role in Cardiovascular Diseases
    Mini Chandra, Sumitra Miriyala, Manikandan Panchatcharam · 2017 · PPAR Research
41. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
    Masato Yoneda, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Kento Imajo, Anna Ozaki, Asako Nogami, Masataka Taguri, Takeharu Yamanaka et al. · 2021 · BMJ Open Diabetes Research & Care
42. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
    Guntram Schernthaner, Anthony H Barnett, D. J. Betteridge, Rafael Carmena, Antonio Ceriello, Bernard H. Charbonnel, M Hanefeld, Roger Lehmann, Maciej Tadeusz Malecki, Richard W. Nesto et al. · 2010 · Diabetologia
43. Considerations for management of fluid dynamic issues associated with thiazolidinediones
    Norman K. Hollenberg · 2003 · The American Journal of Medicine
44. Energy Partitioning in Gluteal-Femoral Fat: Does the Metabolic Fate of Triglycerides Affect Coronary Heart Disease Risk?
    Isabelle Lemieux · 2004 · Arteriosclerosis Thrombosis and Vascular Biology
45. PPAR-γ Agonists and Their Role in Type 2 Diabetes Mellitus Management
    Valmore Bermúdez, Freddy Finol, Nailyn Parra, Maria Parra, Adriana Pérez, Lianny Peñaranda, Daviel Vílchez, Joselyn Rojas, Nailet Arráiz, Manuel Velasco · 2010 · American Journal of Therapeutics
46. Current Management Strategies for Coexisting Diabetes Mellitus and Obesity
    André Jacques Scheen · 2003 · Drugs
47. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
    Wang Soo Lee, Jaetaek Kim · 2015 · PPAR Research
48. Recent findings concerning thiazolidinediones in the treatment of diabetes
    Guenther H. Boden, Meijuan Zhang · 2006 · Expert Opinion on Investigational Drugs
49. Impact of weight gain on outcomes in type 2 diabetes
    Stuart A. Ross, Grzegorz Jan Dzida, Jiten P Vora, Kamlesh K. Khunti, Marcel Kaiser, Robert J. Ligthelm · 2011 · Current Medical Research and Opinion
50. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus
    Tetsuya Teranishi, Takeshi Ohara, Kengo Maeda, Masako Zenibayashi, Kunichi Kouyama, Yushi Hirota, Hideaki Kawamitsu, Masahiko Fujii, Kazuro Sugimura, Masato Kasuga · 2007 · Metabolism
51. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
    Esther Phielix E, Julia Szendroedi, Michael Roden · 2011 · Trends in Pharmacological Sciences
52. Free fatty acids and type 2 diabetes mellitus
    Kathleen Louise Wyne · 2003 · The American Journal of Medicine
53. Pioglitazone initiation and subsequent hospitalization for congestive heart failure
    A Karter, Ali Ahmed, J. Liu, H.M. Moffet, Margaret M. Parker · 2005 · Diabetic Medicine
54. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes
    Glyn Belcher, Ceri Lambert, Gareth Edwards, Richard Urquhart, David Richard Matthews · 2005 · Diabetes Research and Clinical Practice
55. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
    Y. Miyazaki, Ralph A. DeFronzo · 2008 · Diabetes Obesity and Metabolism
56. Pioglitazone Increases the Proportion of Small Cells in Human Abdominal Subcutaneous Adipose Tissue
    Tracey McLaughlin, Tingting Liu, Gail Yee, Fahim Abbasi, Cindy A. Lamendola, Gerald M. Reaven, Philip S. Tsao, Samuel W. Cushman, Arthur Sherman · 2009 · Obesity
57. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women
    Mirja Tiikkainen, Robert Bergholm, Aila Rissanen, Antti Aro, Irma Salminen, Marjo Tamminen, Kari Teramo, Hannele Yki‐Järvinen · 2004 · American Journal of Clinical Nutrition
58. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
    Bogdan Balas, Renata Belfort, Stephen A. Harrison, Celia Darland, Joan Finch, Steven Schenker, Amalia Gastaldelli, Kenneth J. Cusi · 2007 · Journal of Hepatology
59. Effect of Pioglitazone on HIV-1-Related Lipodystrophy: A Randomized Double-Blind Placebo-Controlled Trial (ANRS 113)
    Laurence Slama, Émilie Lanoy, Marc‐Antoine Valantin, Jean‐Philippe Bastard, Aziza Chermak, Amal Boutekatjirt, Demiana William Faltaos, Eric Billaud, Jean‐Michel Molina, Jacqueline Capeau et al. · 2008 · Antiviral Therapy
60. The Effect of Pioglitazone on the Liver
    Amalia Gastaldelli, Yoshinori Miyazaki, Archana Mahankali, Rachele Berria, Maura Pettiti, Emma Buzzigoli, Eleuterio Ferrannini, Ralph A. DeFronzo · 2006 · Diabetes Care
61. Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
    Mandeep Singh Bajaj, Rais Baig, Swangjit Suraamornkul, Lou Jean Hardies, Dawn K. Coletta, Gary W. Cline, Adriana Monroy, Shailja Koul, Apiradee Sriwijitkamol, Nicolas Musi et al. · 2010 · The Journal of Clinical Endocrinology & Metabolism
62. MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema
    Francine M. Gregoire, Fang Zhang, Holly J. Clarke, Thomas A. Gustafson, Dorothy D. Sears, Svetlana Favelyukis, James M. Lenhard, Dennis Rentzeperis, L. Edward Clemens, Yi Mu et al. · 2009 · Molecular Endocrinology
63. Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus
    Rachele Berria, Leonard C. Glass, Archana Mahankali, Y. Miyazaki, Adriana Monroy, Eleanna De Filippis, Kenneth J. Cusi, Eugênio Cersósimo, Ralph Anthony DeFronzo, Amalia Gastaldelli · 2007 · Clinical Pharmacology & Therapeutics
64. Thiazolidinediones, insulin resistance and obesity: finding a balance
    John P.H. Wilding · 2006 · International Journal of Clinical Practice
65. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment
    Gabriella Garruti, Raffaella Depalo, Maria Grazia Vita, Filomenamila Lorusso, Federica Giampetruzzi, Aurelia Bellomo Damato, Francesco Giorgino · 2009 · Reproductive BioMedicine Online
66. Rosiglitazone RECORD study: glucose control outcomes at 18 months
    Philip Home, N. P. Jones, Stuart Pocock, Henning Beck‐Nielsen, Ramón Gomis, Markolf Hanefeld E, Michel Komajda N, Paula S. Curtis, for the RECORD Study Group · 2007 · Diabetic Medicine
67. Depot-specific effects of the PPARγ agonist rosiglitazone on adipose tissue glucose uptake and metabolism
    William T. Festuccia, Pierre-Gilles Blanchard, Véronique Turcotte, Mathieu Laplante, Meltem Sarıahmetoğlu, David N. Brindley, Yves Deshaies · 2009 · Journal of Lipid Research
68. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis
    Zhou, Yue, Huang, Yajing, Ji, Xiaoyun, Wang, Xiang, Shen, Liyan, Wang, Yangang · 2020 · The Journal of Clinical Endocrinology & Metabolism
69. Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review
    Paresh Dandona, Sandeep Dhindsa, Husam Ghanim, Farid Saad · 2020 · Diabetes Obesity and Metabolism
70. Pediatric non-alcoholic fatty liver disease: Preventive andtherapeutic value of lifestyle intervention
    Valério Nobili, Anna Alisi, Massimiliano Raponi · 2009 · World Journal of Gastroenterology
71. Effects of green tea on insulin sensitivity, lipid profile and expression of PPARα and PPARγ and their target genes in obese dogs
    Samuel Serisier, Véronique Leray, Wilfried Poudroux, Thierry Magot, Khadija Ouguerram, Patrick Nguyen · 2007 · British Journal Of Nutrition
72. Genetic Predisposition to Central Obesity and Risk of Type 2 Diabetes: Two Independent Cohort Studies
    Tao Huang, Qibin Qi, Yan Zheng, Sylvia H. Ley, JoAnn Elisabeth Manson, Frank B. Hu, Lu Qi · 2015 · Diabetes Care
73. Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets
    Jacob George, Christopher Liddle · 2007 · Molecular Pharmaceutics
74. The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
    Mahmoud M Mansour · 2014 · Progress in molecular biology and translational science
75. Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy
    Jean Y. Park, Angeline Y. Chong, Elaine K. Cochran, David Erwin Kleiner, Michael J. Haller, Desmond Schatz, Phillip Görden · 2007 · The Journal of Clinical Endocrinology & Metabolism
76. LKB1 and AMPK and the regulation of skeletal muscle metabolism
    Koh, Ho-Jin, Brandauer, Josef, Goodyear, Laurie J · 2008 · Current Opinion in Clinical Nutrition and Metabolic Care
77. Adipose tissues as endocrine target organs
    Nicolas Lanthier, Isabelle Anne Leclercq · 2014 · Best Practice & Research Clinical Gastroenterology
78. Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments
    Érika Aparecida Silveira, Golnaz Vaseghi, Annelisa Silva e Alves de Carvalho Santos, Nathalie Kliemann, Farzad Masoudkabir, Mark A. Noll, Noushin Mohammadifard, Nizal Sarrafzadegan, Cesar Messias de Oliveira · 2020 · International Journal of Molecular Sciences
79. Plasma monocyte chemoattractant protein‐1 (MCP‐1) and macrophage inflammatory protein‐1α are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment
    Glintborg, Dorte, Andersen, Marianne, Richelsen, Bjørn, Bruun, Jens M. · 2009 · Clinical Endocrinology
80. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
    Muhammad A Abdul‐Ghani, Amin Jayyousi, Ralph A. DeFronzo, Nidal Asaad, Jassim M. S. Al Suwaidi · 2017 · Current Vascular Pharmacology
81. Thiazolidinediones for the treatment of type 2 diabetes
    J.W.F. Elte, Jean‐Frédéric Blickle · 2007 · European Journal of Internal Medicine · Retracted
82. Therapeutic Trials in Nonalcoholic Steatohepatitis
    Vlad Ratziu, Stephen Hugh Caldwell, Brent A. Neuschwander‐Tetri · 2010 · Hepatology
83. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli, A., Formoso, G. · 2013 · Diabetes, Obesity and Metabolism
84. Distribution of Abdominal Visceral and Subcutaneous Adipose Tissue and Metabolic Syndrome in a Korean Population
    Soyeun Kim, Belong Cho, Hyejin Lee, K. M. Choi, Seung-Sik Hwang, Donghee Kim, Kyoungwoo Kim, Hyuktae Kwon · 2011 · Diabetes Care
85. Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content
    Ravikumar Balasubramanian, Jean Gerrard, Chiara Dalla Man, Michael Firbank, Annette P. Lane, Philip T. English, Claudio Cobelli, Roy Taylor · 2008 · Diabetes
86. Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression
    Ping Wang, Johan Renes, Freek G. Bouwman, Annelies Bunschoten, Edwin C.M. Mariman, Jaap Keijer · 2007 · Diabetologia
87. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes
    Toshikazu Yamanouchi, T. Sakai, K. Igarashi, Kaoru Ichiyanagi, Hiroshi Watanabe, T. Kawasaki · 2005 · Diabetic Medicine
88. Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases
    Ibrahim AlZaim, Safaa H. Hammoud, Houssam Al-Koussa, Alaa Ghazi, Ali Hussein Eid, Ahmed Fawzy EL‐Yazbi · 2020 · Frontiers in Cardiovascular Medicine
89. Weight gain in type 2 diabetes mellitus
    A. N. Jacob, Kevin R. Salinas, BEVERLEY A. ADAMS-HUET, Philip Raskin · 2006 · Diabetes Obesity and Metabolism
90. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
    Hyejin Yoon · 2014 · World Journal of Hepatology
91. The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
    Amalia Gastaldelli, Yoshinori Miyazaki, Maura Pettiti, Eleonora Santini, Demetrio Ciociaro, Ralph Anthony DeFronzo, Ele Ferrannini · 2006 · The Journal of Clinical Endocrinology & Metabolism
92. Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
    Muhammad A. Abdul-Ghani, Pietro Maffei, Ralph Anthony DeFronzo · 2024 · The Lancet Diabetes & Endocrinology
93. Two Faces of White Adipose Tissue with Heterogeneous Adipogenic Progenitors
    Injae Hwang, Jae Bum Kim · 2019 · Diabetes & Metabolism Journal
94. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes
    Meng Hee Tan, Don Johns, Jorma Strand, Johan Halse, Sten Madsbad, Jan W. Eriksson, J. Clausen, Christopher S. Konkoy, Matthias Herz, for the GLAC Study Group · 2004 · Diabetic Medicine
95. Combined Thiazolidinedione-Insulin Therapy
    A J Scheen · 2004 · Drug Safety
96. Thiazolidinediones and their Fluid-Related Adverse Effects
    Janaka J. Karalliedde, Robin E. Buckingham · 2007 · Drug Safety
97. The current role of thiazolidinediones in diabetes management
    Christos V. Rizos, Anastazia A. Kei, Moses Elisaf · 2016 · Archives of Toxicology
98. Metformin Reduces Body Weight Gain and Improves Glucose Intolerance in High-Fat Diet-Fed C57BL/6J Mice
    Yukari Matsui, Yasushi Hirasawa, Takahiro Sugiura, Tohru Toyoshi, Kohei Kyuki, Mikio Ito · 2010 · Biological and Pharmaceutical Bulletin
99. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)
    Surjit Singh, Anil Kumar Bhansali · 2016 · BMC Dermatology
100. Thiazolidinediones ? some recent developments
     Michael Stümvoll · 2003 · Expert Opinion on Investigational Drugs